10% OFF EVERYTHING
Ends July 31Shop the sale
Third-party tested
Discreet shipping
Back to Research Blog
Growth Factor Research

Tesamorelin: A Stabilized GHRH Analog in GH-Axis Research

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone. This overview surveys its secretagogue mechanism, the GH/IGF-1 axis it engages, and the structural changes that extend its stability.

Purely Peptides Research TeamJuly 21, 20267 min read
TesamorelinGHRHgrowth hormoneIGF-1somatotrophsecretagogue research
Research Use Only. All compounds discussed are sold exclusively for laboratory and in vitro research purposes. Nothing on this page constitutes medical advice or recommendation for human use.

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone, GHRH(1-44). It belongs to the secretagogue class of research peptides — compounds that act upstream of the pituitary to stimulate the endogenous release of growth hormone (GH), rather than supplying GH directly. That upstream position makes it a useful tool for studying the physiology of the GH/IGF-1 axis in a way that preserves normal feedback regulation in model systems.

Secretagogue Mechanism

Tesamorelin binds the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and release. Because it engages the receptor for endogenous GHRH, its GH-releasing activity in research models remains subject to the normal regulatory brakes of the axis, including somatostatin tone and IGF-1 feedback — a contrast with direct GH administration.

Structural Stabilization

Native GHRH is rapidly degraded, primarily by dipeptidyl peptidase-4 (DPP-4). Tesamorelin carries an N-terminal trans-3-hexenoyl modification that confers resistance to this degradation, extending its stability relative to native GHRH. It is a common reference compound in structure-stability studies of GHRH-family peptides.

Research Applications

  • GH/IGF-1 axis physiology and feedback-regulation models
  • Somatotroph signaling and GHRH-receptor pharmacology
  • Comparative secretagogue studies (GHRH analogs vs ghrelin-receptor agonists)
  • DPP-4 resistance and peptide-stabilization research
  • Bone and connective-tissue repair models within the GH axis

References

  1. Ferdinandi ES, Brazeau P, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007. PMID: 17214611.
  2. Frohman LA, Downs TR, Heimer EP, et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989. PMID: 2565342.

This article summarizes publicly available research for educational purposes and does not constitute medical advice, a therapeutic claim, or a recommendation for human use. Products referenced are sold for laboratory research use only.

Research Compounds Discussed